Document Detail


The Determination of Arsenic Metabolites in Patients with Newly Diagnosed Acute Promyelocytic Leukemia Treated with Arsenic Trioxide.
MedLine Citation:
PMID:  23343178     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
ABSTRACT The efficacy of arsenic trioxide (ATO) in the treatment of acute promyelocytic leukemia (APL) is widely accepted. It is necessary to determine the concentration of arsenic since it is a poisonous drug as we all known. The profiles of arsenic speciation in patients with relapsed or refractory APL had been shown in few reports. Arsenic metabolites concentrations in plasma of patients with newly diagnosed APL during the first course of arsenic remission induction therapy were first determined and the complicated change regularity of these metabolites concentrations in this phase was first described in our study. We demonstrated the concentration of trivalent inorganic arsenic (As(III)), which is regarded as the most effective and poisonous, was much lower than other metabolites. Concentrations of the same arsenic metabolites were obviously distinct among various individuals We infer that determination of metabolites separately is necessary, can not be replaced by total arsenic determination. In addition, the amount of arsenic methylated metabolites increased in the first course of ATO therapy, which might play a more and more important pole. Further research should be done to study the relationship between arsenic metabolites concentrations and efficacy, side effects of patients with APL treated with ATO.
Authors:
Zhang Zhuo; Chen Yan; Meng Hongbin; Sui Meijuan; Zhou Qian; Shi Ce; Han Lina; Wang Hong; Zhou Jin
Related Documents :
8671368 - Recovery of corpus luteum function after prolonged deprivation from gonadotrophin stimu...
10685528 - Human chorionic gonadotropin administration does not increase plasma androgen levels in...
9696228 - Effects of the neuropeptide y on estradiol and progesterone secretion by human granulos...
8530648 - The empty follicle syndrome: a pharmaceutical industry syndrome.
6384568 - Acute effect of atenolol on hemodynamic, plasma renin activity and plasma aldosterone c...
8329828 - Intranasal administration of growth hormone-releasing hormone(1-29)-nh2 in children wit...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-24
Journal Detail:
Title:  Leukemia & lymphoma     Volume:  -     ISSN:  1029-2403     ISO Abbreviation:  Leuk. Lymphoma     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-24     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9007422     Medline TA:  Leuk Lymphoma     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Preliminary results of radiotherapy for primary intraocular non-Hodgkin's lymphoma.
Next Document:  Patterns of use of FDG-PET for the initial staging of grade 1-2 follicular lymphoma and its impact o...